AS DRUGS companies increasingly focus on how different groups of patients
respond to a particular medication, a study has shown for the first time that
grouping people by race is not the best way to do this.
“It’s a great step forward to show that race labels are not needed as a
guide,” says Rochelle Long, programme director of the Pharmacogenetics Research
Network at the US National Institutes of ÎçÒ¹¸£Àû1000¼¯ºÏ.
Many modern trials look at whether particular ethnic groups might be more or
less sensitive to the drug being tested. Companies can now try to get approval
for a drug…
